Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.57 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | CCR2 | P41597 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156783 | 0.92 | CCR2 (0.52) | MAPK1SMN1; SMN2MTNR1AMTNR1BBRD4 | |
| SCHEMBL2156788 | 0.91 | DRD4 (0.50) | MAPK1SMN1; SMN2MTNR1AMTNR1BBRD4 | |
| SCHEMBL2156760 | 0.89 | CCR2 (0.51) | MAPK1SMN1; SMN2MTNR1AMTNR1BBRD4 | |
| SCHEMBL3199231 | 0.86 | MAPK1 (0.56) | MAPK1SMN1; SMN2MTNR1AMTNR1BBRD4 | |
| SCHEMBL26473 | 0.83 | MTNR1B (0.67) | MAPK1SMN1; SMN2MTNR1AMTNR1BCCR2 | |
| SCHEMBL2156733 | 0.83 | CCR2 (0.48) | MAPK1SMN1; SMN2MTNR1AMTNR1BBRD4 | |
| SCHEMBL13485078 | 0.82 | MAPK1 (0.52) | MAPK1SMN1; SMN2MTNR1AMTNR1BCYP19A1 | |
| SCHEMBL6778354 | 0.82 | MTNR1B (0.66) | MTNR1AMTNR1BBRD4CCR2CYP19A1 | |
| SCHEMBL14529788 | 0.81 | SMN1; SMN2 (0.65) | MAPK1SMN1; SMN2BRD4CYP19A1KMT2A | |
| SCHEMBL3203921 | 0.81 | PLA2G2A (0.56) | MAPK1SMN1; SMN2MTNR1AMTNR1BPLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5919943-A | INHIBITION OF SPLA2 | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | claimed |
| EP-2341045-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid (acyloxy)alkyl or ((alkoxycarbonyl)oxy)alkyl ester as SPLA2 inhibitor | Eli Lilly and Company (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-1950200-A1 | [[3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-11H-indol-4-yl]oxy]acetic acid methyl ester as sPLA2 inhibitor | ELI LILLY AND COMPANY (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1073440-B1 | sPLA 2 INHIBITOR ESTERS | LILLY CO ELI (US) | 2004-10-20 | — | — | EP | disclosed |
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | LOH ANDREW (US) | 2004-06-10 | — | — | US | disclosed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| US-6433001-B1 | SEPTIC SHOCK, ALLERGIC RHINITIS, RHEUMATIC ARTHRITIS, ADULT RESPIRATORY DISTRESS SYNDROME, BRONCHIAL ASTHMA, TRAUMA, AND PANCREATITIS TREATMENT | ELI LILLY AND COMPANY | 2002-08-13 | — | — | US | disclosed |
| EP-1073440-A4 | sPLA 2 INHIBITOR ESTER | LILLY CO ELI (US) | 2002-07-17 | — | — | EP | disclosed |
| EP-0675110-B1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | LILLY CO ELI (US) | 2002-07-10 | — | — | EP | disclosed |
| EP-1197484-A2 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2002-04-17 | — | — | EP | disclosed |
| US-6274578-B1 | ((3-(2-AMINO-1,2-DIOXOETHYL)-2-METHYL-1-(PHENYLMETHYL)-1H--IND OL-4-YL)OXY)ACETIC ACID N-MORPHOLINO ETHYL ESTER; RESPIRATORY SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2001-08-14 | — | — | US | disclosed |
| EP-1081135-A2 | 1H-indole-3-glyoxylamide spla2 inhibitors | ELI LILLY AND COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1073440-A1 | sPLA 2 INHIBITOR ESTERS | ELI LILLY AND COMPANY (US) | 2001-02-07 | — | — | EP | disclosed |
| US-6175021-B1 | HUMAN NON-PANCREATIC SECRETORY PHOSPHOLIPASE A2 (SPLA2); INHIBITS RELEASE OF ARACHIDONIC ACID TO TREAT SEPTIC SHOCK; ((3-(2-AMINO-1,2-DIOXOETHYL)-2-METHYL-1-(PHENYLMETHYL)-1H-INDOL-4 -YL)OXYLACETIC ACID, FOR EXAMPLE | ELI LILLY AND COMPANY | 2001-01-16 | — | — | US | disclosed |
| WO-1999056752-A1 | sPLA2 INHIBITOR ESTER | ELI LILLY AND COMPANY (US) | 1999-11-11 | — | — | WO | disclosed |
| US-5919943-A | INHIBITION OF SPLA2 | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5919810-A | SEPTIC SHOCK | ELI LILLY AND COMPANY (US) | 1999-07-06 | — | — | US | disclosed |
| US-5733923-A | SECRETORY PANCREATIC PHOSPHOLIPASE A2 | ELI LILLY AND COMPANY (US) | 1998-03-31 | — | — | US | disclosed |
| US-5654326-A | SEPTIC SHOCK; HUMAN NONPANCREATIC SECRETORY PHOSPHOLIPASE | ELI LILLY AND COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0675110-A1 | 1H-Indole-3-glyoxylamide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110825-A1 | Administration of an enzyme inhibitor of human non-pancreatic scretory phospholipase A2 (sPLA2) if activity levels are high or on the rise; treating within 0-24 hours after first organ failure and continuing as necessary, i.e., 1-7 days | PLA2G12A, PLA2G2E, PLA2G3 | MAPK1 3651/4885SMN1; SMN2 674/4885MTNR1A 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.